Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used.

van Griensven J, Sopheak T, Koole O, Verpooten GA, Lynen L.

J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):e21-3. doi: 10.1097/QAI.0b013e3182199f00. No abstract available.

PMID:
21709448
2.

Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.

Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C Jr, Klein D.

J Acquir Immune Defic Syndr. 2010 Jan;53(1):62-9. doi: 10.1097/QAI.0b013e3181be6be2.

PMID:
19838127
3.

Tenofovir and didanosine: a dangerous liaison.

Waters L, Maitland D, Moyle GJ.

AIDS Read. 2005 Aug;15(8):403-6, 413. Review. No abstract available.

PMID:
16110555
4.

Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.

Wever K, van Agtmael MA, Carr A.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):78-81. doi: 10.1097/QAI.0b013e3181d05579.

PMID:
20173649
5.

Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals.

Lanzafame M, Lattuada E, Rapagna F, Gottardi M, Vento S.

Clin Infect Dis. 2006 Jun 1;42(11):1656-7; author reply 1658. No abstract available.

PMID:
16652329
6.

[Conclusions. Tenofovir].

Mallolas J.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:62-4. Spanish. No abstract available.

PMID:
19195439
7.

HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.

[No authors listed]

AIDS Patient Care STDS. 2009 Aug;23(8):680-1. No abstract available.

PMID:
19694040
8.

Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?

Masiá M, Gutiérrez F, Padilla S, Ramos JM, Pascual J.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):427-8. No abstract available.

PMID:
15097160
9.

The role of drug interactions and monitoring in the prevention of tenofovir-associated kidney disease.

Winston JA, Shepp DH.

Clin Infect Dis. 2006 Jun 1;42(11):1657-8; author reply 1658. No abstract available.

PMID:
16652330
10.

Progression of renal impairment under therapy with tenofovir.

Jülg BD, Bogner JR, Crispin A, Goebel FD.

AIDS. 2005 Aug 12;19(12):1332-3. No abstract available.

PMID:
16052093
11.

Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.

Cicconi P, Bongiovanni M, Melzi S, Tordato F, d'Arminio Monforte A, Bini T.

Int J Antimicrob Agents. 2004 Sep;24(3):284-5.

PMID:
15325433
12.

The art of managing human immunodeficiency virus infection: a balancing act.

Reiss P.

Clin Infect Dis. 2009 Nov 15;49(10):1602-4. doi: 10.1086/644770. No abstract available.

PMID:
19842978
13.

Tenofovir disoproxil fumarate.

Antoniou T.

Drugs. 2003;63(15):1609-10. No abstract available.

PMID:
12887266
14.

Editorial comment: tenofovir-related nephrotoxicity--who's at risk?

Gupta Samir K.

AIDS Read. 2007 Feb;17(2):102-3. No abstract available.

PMID:
17323509
15.
16.

Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.

Winston J, Shepp DH.

HIV Med. 2006 Oct;7(7):484-5. No abstract available.

17.
18.

[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].

Pulido F, Fiorante S.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:13-8. Review. Spanish.

PMID:
19195433
19.

Effect of tenofovir on renal glomerular and tubular function.

Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H.

AIDS. 2007 Jul 11;21(11):1483-5.

PMID:
17589197
20.

Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases.

Sabbatini F, Prati F, Borghi V, Bedini A, Esposito R, Mussini C.

Infection. 2007 Dec;35(6):474-6. Epub 2007 Nov 22. No abstract available.

PMID:
18034206

Supplemental Content

Support Center